CAR T-cell Therapy
TIL Therapy for Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
MDM2 Inhibitor
Navtemadlin + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 1
Goodyear, Arizona
This trial studies the effects of navtemadlin and radiation therapy in patients with soft tissue sarcoma. Navtemadlin helps stop cancer cells from growing, and radiation therapy kills them with high-energy x-rays. The goal is to shrink the tumor before surgery to remove less normal tissue. Navtemadlin is a newer drug being tested for its ability to stop cancer cells from growing.
Hyperbaric Oxygen Therapy for Sarcoma
Recruiting3 awardsPhase 4
Durham, North Carolina
This trial is testing if breathing pure oxygen in a pressurized room can help patients with leg sarcoma heal better after surgery and radiation. The extra oxygen might speed up their recovery. Hyperbaric oxygen therapy (HBOT) has been shown to have beneficial effects in the treatment of late radiation sequelae.
Popular Filters
Trials for STS Patients
Anti-tumor antibiotic
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Procedure
DW-MRI for Sarcoma in Young Patients
Recruiting1 award
Memphis, Tennessee
This trial is testing whether a method that doesn't involve radiation (DW-MRI) can be used instead of current methods (CT, nuclear bone scan, PET-CT) to measure how well children with sarcomas are responding to therapy, in order to reduce exposure to harmful effects of ionizing radiation.
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Trials for Rhabdomyosarcoma Patients
Anti-tumor antibiotic
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Procedure
DW-MRI for Sarcoma in Young Patients
Recruiting1 award
Memphis, Tennessee
This trial is testing whether a method that doesn't involve radiation (DW-MRI) can be used instead of current methods (CT, nuclear bone scan, PET-CT) to measure how well children with sarcomas are responding to therapy, in order to reduce exposure to harmful effects of ionizing radiation.
Trials for Metastatic Patients
Anti-tumor antibiotic
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Phase 3 Trials
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Radiation Therapy
IMRT for Soft Tissue Sarcoma
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial will compare the short-term wound healing complications of patients with extremity or truncal soft tissue sarcoma who receive preoperative image guided radiation therapy (IGRT) delivered using intensity modulated radiation therapy (IMRT) to those who receive surgery followed by postoperative IGRT.
Monoclonal Antibodies
Immunotherapy + Chemotherapy for Sarcoma
Recruiting2 awardsPhase 3
Newark, Delaware
"This trial is comparing the effects of combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) versus using chemotherapy alone to treat patients with undifferentiated pleomorphic sar
Trials With No Placebo
Alkylating agent
Lurbinectedin for Ewing Sarcoma
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial is testing a medication called lurbinectedin in children and young adults who have already been treated for solid tumors or have a type of cancer called Ewing sarcoma that has come back or didn't respond to other treatments. The medication aims to stop cancer cells from growing and spreading. The study will check if the treatment is safe and effective.
Anti-tumor antibiotic
Retifanlimab + Chemotherapy for Soft Tissue Sarcoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a new drug, Retifanlimab, to see if it is safe and effective when combined with two existing chemotherapy drugs, gemcitabine and docetaxel, to treat patients with soft tissue sarcoma.
Procedure
Intratumoral Microdosing for Cancer
Recruiting1 awardPhase < 1
Shreveport, Louisiana
This trial uses a device to inject small amounts of cancer drugs directly into tumors of patients undergoing surgery. The device marks where each drug is injected, allowing researchers to see how different parts of the tumor respond. This helps test cancer drugs early without causing widespread side effects. The device has been shown to induce strong, easily tracked, drug-specific responses in tumors while avoiding toxicity, setting the stage for its application in clinical trials.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.